Patent Overview: Battery-Operated Handheld Tissue Oximeter

United States Patent 12721552, titled “Battery-operated handheld tissue oximeter,” was assigned to ViOptix, Inc. The patent discloses an all-in-one, compact medical monitoring device engineered to measure tissue oxygen saturation without requiring a pulse or external tethered processing console.

The device comprises an enclosure housing a processor, memory, battery, integrated display, and a specialized probe tip. The probe tip features an optical sensor array with multiple sensor openings positioned at defined, non-uniform distances from light sources. This geometric configuration enables the device to execute spatially-resolved spectroscopy by capturing light reflected from varying tissue depths, processing the signals internally, and displaying real-time oxygen saturation values directly on the handheld unit.

Key Technological Innovations

The patented invention introduces several engineering advancements that distinguish it from standard pulse oximeters and traditional continuous-wave tissue monitors:

• Fully Integrated Form Factor: Traditional spatially-resolved spectroscopy instruments rely on bulky external consoles, wall power, and fiber-optic cables. This design houses all operational components, including the power source, signal acquisition processor, measurement module, and display, within a single handheld enclosure under ten inches in length.
• Spatially-Resolved Spectroscopy (SRS) Geometry: The probe face utilizes discrete source-to-detector distances arranged in circular patterns. This geometric variation allows the system to differentiate tissue absorption from scattering coefficients, providing absolute oxygen saturation values without relying on assumed scattering parameters.
• Non-Pulsatile Tissue Assessment: Unlike pulse oximeters that depend on arterial pulsation to calculate absorption, this tissue oximeter evaluates local microvascular oxygenation through diffuse optical reflectance. It can accurately measure oxygenation in isolated tissue flaps, skin grafts, and reattached limbs that lack an active pulse.
• Dynamic Thermal Compensation: Temperature sensors placed adjacent to the light-emitting diodes measure thermal shifts during operation. The system processor dynamically adjusts the duty cycle of the LED drive signal to maintain consistent light output as operational temperatures fluctuate.
• Integrated Contact Pressure Sensing: The probe structure accommodates a pressure sensor to measure force against patient tissue. This feature ensures adequate contact to block ambient light while alerting clinicians if excessive pressure is applied that could restrict local blood flow.

The patent incorporates disclosures building upon ongoing tissue oximetry research by ViOptix inventors, including Heaton et al., Lash et al., and Mao et al., whose work in multi-wavelength optical probe design forms part of the underlying patent family history.

Recognition as Patent of the Month (October 2026)

The device earned recognition as Patent of the Month for October 2026 in the pharma, medical devices, and healthcare category due to its practical approach to intraoperative tissue monitoring. Reconstructive and plastic surgeons frequently need to assess tissue flap viability during surgery, where undetected ischemia can lead to tissue necrosis and surgical failure. Previous intraoperative monitoring options often required trade-offs between portability and measurement accuracy. By implementing full spatially-resolved spectroscopy into an ergonomic, single-user handheld wand, ViOptix, Inc. addressed a longstanding clinical need. The combination of immediate point-of-care feedback, self-calibration mechanisms, and optical artifact rejection makes the technology directly applicable to surgical workflows.

U.S. R&D Tax Credit Eligibility for Practical Applications

Companies involved in the design, engineering, and practical application of technologies detailed in this patent may qualify for the United States Research and Development (R&D) Tax Credit under Internal Revenue Code Section 41. To meet the federal four-factor test, development activities must aim to create or improve the functionality, performance, or reliability of a medical device product or process. In developing handheld SRS tissue oximeters, engineering teams address technical uncertainties surrounding optical ray-tracing geometries, thermal drift compensation algorithms, low-noise printed circuit board layout, and miniaturized power management. These initiatives rely on principles of biomedical engineering, optical physics, electrical engineering, and computer science. The development workflow involves systematic trial and error through physical prototyping, Monte Carlo computer simulation modeling, and clinical bench testing. Qualifying expenditures generally include internal direct engineering wages, prototype supply costs, and third-party contract research expenses incurred during the development process.